Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICEATM

This article was originally published in The Rose Sheet

Executive Summary

No public comments were received on the "Addendum to the ICCVAM Evaluation of In Vitro Test Methods for Detecting Potential Endocrine Disruptors: Estrogen Receptor and Androgen Receptor Binding and Transcriptional Activation Assays," the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods states in a Sept. 28 Federal Register 1notice. The document is available on the NICEATM Web site. NTP had requested comments on the addendum when it was published in a March 16 Federal Register notice. The addendum proposed replacing four substances from a list proposed for validation of the screening methods (2"The Rose Sheet" March 20, 2006, In Brief)...

You may also be interested in...



ICCVAM

Addendum to the ICCVAM Evaluation of In Vitro Test Methods for Detecting Potential Endocrine Disruptors: Estrogen Receptor and Androgen Receptor Binding and Transcriptional Activation Assays published in a March 16 Federal Register notice includes recommendation by Interagency Coordinating Committee on the Validation of Alternative Methods to replace four substances that are not commercially available or have restricted availability - anastrazole, CGS 18320B, fadrozole and ICI 182,780 - with 4-hydroxyandrostenedione, chrysin, dicofol and raloxifene HCl. ICCVAM published final report containing minimum procedural standards for standardization and validation of in vitro estrogen and androgen receptor binding and transcriptional activation assays in 2003 (1"The Rose Sheet" June 16, 2003, In Brief). Comments on addendum, which also identifies six other substances that could be replaced, are due May 1...

EU GMP Annex I Proposal Would Maintain PUPSIT, Relax WFI Restrictions

The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.

Coronavirus Drives TCM Sales In China, Clouds Global Consumer Health Outlook

Consumer health product firms say the coronavirus will have an impact on their results, but it’s too early to estimate the costs. US FDA also hedges its predictions, saying the outbreak could lead to interruptions in country’s drug and medical device supplies. China's health commission has issued six guidelines for diagnosis and treatment, but no conventional antiviral treatment is approved and it's emphasizing traditional Chinese medicines.

UsernamePublicRestriction

Register

RS014246

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel